We are live on ! Find out more
WS

Wedbush Securities Portfolio holdings

AUM $3.43B
1-Year Est. Return 24.13%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+24.13%
3 Year Est. Return
+79.76%
5 Year Est. Return
+94.69%
10 Year Est. Return
+325.94%
AUM
$771M
AUM Growth
+$32.5M
Cap. Flow
+$15.2M
Cap. Flow %
1.97%
Top 10 Hldgs %
16.24%
Holding
916
New
72
Increased
419
Reduced
247
Closed
78

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$1.52M
2
VST icon
Vistra
VST
+$1.08M
3
ETP
Energy Transfer Partners, L.P.
ETP
+$1,000K
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$971K
5
AAPL icon
Apple
AAPL
+$804K

Top Sells

Rank Stock Value
1
TRR
Trc Companies
TRR
+$9.24M
2
GGP
GGP Inc.
GGP
+$1.5M
3
CNA icon
CNA Financial
CNA
+$1.04M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$779K
5
CVS icon
CVS Health
CVS
+$759K

Sector Composition

Rank Sector Weight
1 Financials 10.7%
2 Healthcare 10.11%
3 Consumer Discretionary 9.02%
4 Technology 8.48%
5 Industrials 8.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NE
776
DELISTED
Noble Corporation
NE
$52K 0.01%
14,343
-100
-0.7% -$460
BNTC icon
777
Benitec Biopharma
BNTC
$394M
$50K 0.01%
+106
New +$67K
FCEL icon
778
FuelCell Energy
FCEL
$1.7B
$49K 0.01%
110
-42
-28% -$18.6K
NSLR
779
Neostellar Capital Corp
NSLR
$262M
$47K 0.01%
12,959
– –
IDXG
780
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$47K 0.01%
+5,250
New +$103K
AFMD
781
DELISTED
Affimed
AFMD
$45K 0.01%
2,200
+700
+47% +$15.5K
SITO
782
DELISTED
SITO MOBILE, LTD
SITO
$45K 0.01%
12,000
-2,000
-14% -$6.73K
LAB icon
783
Standard BioTools
LAB
$326M
$44K 0.01%
11,000
-900
-8% -$4.27K
TA
784
DELISTED
TravelCenters of America LLC
TA
$44K 0.01%
2,150
-2,640
-55% -$63.6K
SRRA
785
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$41K 0.01%
875
– –
HOS
786
DELISTED
Hornbeck Offshore Services, Inc.
HOS
$36K ﹤0.01%
12,883
– –
TOVX icon
787
Theriva Biologics
TOVX
$10.2M
$35K ﹤0.01%
7
+1
+17% +$4.98K
RAD
788
DELISTED
Rite Aid Corporation
RAD
$35K ﹤0.01%
600
-678
-53% -$51.2K
WSCI
789
DELISTED
WSI Industries Inc
WSCI
$33K ﹤0.01%
10,150
– –
CYTO
790
DELISTED
Altamira Therapeutics Ltd
CYTO
$32K ﹤0.01%
1
– –
IMUC
791
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$32K ﹤0.01%
+37,500
New +$61.3K
ARGS
792
DELISTED
Argos Therapeutics, Inc.
ARGS
$32K ﹤0.01%
4,475
+1,300
+41% +$11.1K
IRD
793
Opus Genetics
IRD
$254M
$30K ﹤0.01%
+219
New +$42.6K
UTSI icon
794
UTStarcom
UTSI
$22.7M
$28K ﹤0.01%
3,012
– –
MACK
795
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$28K ﹤0.01%
2,860
+1,208
+73% +$24.7K
RTK
796
DELISTED
Rentech, Inc.
RTK
$27K ﹤0.01%
59,590
+10,500
+21% +$4.65K
ENLV icon
797
Enlivex Ltd
ENLV
$70.7M
$25K ﹤0.01%
63
+38
+152% +$11.5K
JRJC
798
DELISTED
China Finance Online Co., Ltd.
JRJC
$23K ﹤0.01%
1,350
– –
DXTR
799
DELISTED
Dextera Surgical Inc.
DXTR
$21K ﹤0.01%
68,767
+43,074
+168% +$21.8K
MBRX icon
800
Moleculin Biotech
MBRX
$15M
$19K ﹤0.01%
4
– –
30 31
32
33 34

Similar funds

CCM
Check Capital Management Costa Mesa, California $3.44B AUM 9.15% 1-Year Est. Return
SI
Sprott Inc Toronto, Ontario, Canada $3.44B AUM 125.26% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PWP
Perfromance Wealth Partners Hinsdale, Illinois $3.45B AUM 29.14% 1-Year Est. Return
RBA
Richard Bernstein Advisors New York $3.45B AUM 16.24% 1-Year Est. Return
PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Wedbush Securities's Q2 2017 Portfolio in Review

As of Q2 2017, Wedbush Securities held 916 positions worth $771M, up 4.4% from $738M the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Wedbush Securities's Q2 2017 filing shows 72 new, 419 increased, 247 reduced and 78 closed positions. Its largest new stake was Novo Nordisk: 75,326 shares worth $1.61M. The largest sale was Trc Companies, an estimated $9.24M.

By sector, the portfolio is most concentrated in Financials at 11% of assets, up from 11% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Wedbush Securities's largest Q2 2017 buy was Novo Nordisk: 75,326 shares worth $1.61M.
  • Wedbush Securities added most to Apple in Q2 2017, an estimated $804K increase.
  • Wedbush Securities's biggest Q2 2017 reduction was GGP Inc., cutting an estimated $1.5M.
  • Wedbush Securities fully exited Trc Companies in Q2 2017, selling an estimated $9.24M.
  • Wedbush Securities's ten largest holdings make up 16% of its $771M portfolio in Q2 2017.
  • Wedbush Securities opened 72 new positions and closed 78 in Q2 2017.
  • Wedbush Securities's portfolio value rose 4.4% quarter-over-quarter to $771M.

Based on Wedbush Securities's 13F filing for Q2 2017, filed 2 Aug 2017.